We are pleased to announce the recent appointments of Maria V. Cincotta as our VP of Clinical Operations & Program Management and Tu-Anh T. Bui as our VP of CMC & Technical Operations.

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals Proceeds will be used to advance the lead program, a …

Tagworks announces the completion of an investment round led by Meneldor (The Netherlands), Oost NL (The Netherlands), and a syndicate of high net-worth private investors. The proceeds of the financing will be used for the clinical development of Tagworks' lead program.    

A key patent that encompasses the therapeutic application scope of the Click-to-Release platform has been granted in the US (US 10,967,069 B2), further strengthening Tagworks’ IP portfolio. The patent titled “BIO-ORTHOGONAL DRUG ACTIVATION”, covers the invention of the pyridazine elimination reaction that underlies the Click-to-Release approach. The patent protects a …

Tagworks reports the development of a new and highly reactive Click-to-Release reaction in the Journal of the American Chemical Society. Great collaboration between Tagworks and SyMO-Chem, Syncom, TU/e , Avipep and Levena. https://pubs.acs.org/doi/abs/10.1021/jacs.0c00531

Tagworks is pleased to announce that on the 10th of October, it won the World ADC Award for Best Publication during the 10th World ADC Summit 2019 in San Diego. The World ADC Awards exist to commend excellence across nine categories within antibody-drug conjugate research and development. Tagworks applies its Click-to-Release platform …

Tagworks reports that the scope of its proprietary click-to-release reaction can be expanded from the cleavage of carbamates to ethers, potentially allowing more drug types to be released from their click-cleavable ADCs. https://doi.org/10.1002/anie.201800402

In mouse models of ovarian and aggressive colon cancer, Tagworks Pharmaceuticals has demonstrated the potent antitumour effect of the company's 'click-to-release' bioorthogonal chemistry approach. The results are published in the journal Nature Communications Raffaella Rossin, et al., Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity …

In a recent publication in the scientific journal Bioconjugate Chemistry, Tagworks Pharma describes its success in using a bioorthogonal reaction for the selective cleavage of tumor-bound ADCs in mice. This represents a powerful new tool for ADC therapy as it does not rely on the currently used biological activation mechanisms, …

A consortium of five European partners, among which Tagworks Pharmaceuticals, has secured a €6 million grant from the EU Horizon2020 program for their research action entitled In Vivo Click PET Imaging Agents: Improving clinical companion diagnostics - Click-It. Coordinator of the Click-It consortium is the University of Copenhagen and next to …